AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Harpoon Therapeutics Announces Presentation on HPN328 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22, 2019

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that an abstract regarding HPN328 for the treatment of small cell lung cancer has been accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The meeting will be held from October 26-30, 2019 in Boston.

Details of the poster presentation are as follows:

Title: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancerSession Title: Therapeutic Agents: BiologicalSession Date: Tuesday, October 29Session Start Time: 12:30Session End Time: 16:00Location: Hall D, Hynes Convention CenterAbstract Number: C033

HPN328 is Harpoon’s fourth Tri-specific T cell Activating Construct (TriTAC™) candidate in development. HPN328 targets DLL3, a protein highly expressed in a majority of SCLC tumors with limited expression in normal tissues. This selective expression makes DLL3 an attractive drug target for T cell engagers. Harpoon is currently conducting IND-enabling studies and expects to initiate a Phase 1 clinical trial of HPN328 in 2020.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC™) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Contacts:

Harpoon Therapeutics, Inc.Georgia ErbezChief Financial Officer650-443-7400 media@harpoontx.com

Westwicke ICRRobert H. UhlManaging Director858-356-5932 robert.uhl@westwicke.com